Claus Moller-San Pedro Net Worth

The estimated Net Worth of Pedro Claus Juan Moller San is at least $18.9 Million dollars as of 2 December 2020. Claus San owns over 50,000 units of Y-Mabs Therapeutics Inc stock worth over $8,058,911 and over the last 6 years he sold YMAB stock worth over $9,870,500. In addition, he makes $967,497 as Chief Executive Officer and Director at Y-Mabs Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Claus Pedro YMAB stock SEC Form 4 insiders trading

Claus has made over 4 trades of the Y-Mabs Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 50,000 units of YMAB stock worth $2,560,500 on 2 December 2020.

The largest trade he's ever made was selling 200,000 units of Y-Mabs Therapeutics Inc stock on 13 May 2020 worth over $7,310,000. On average, Claus trades about 35,394 units every 100 days since 2018. As of 2 December 2020 he still owns at least 607,303 units of Y-Mabs Therapeutics Inc stock.

You can see the complete history of Claus San stock trades at the bottom of the page.

Claus Moller-San Pedro biography

Dr. Claus Juan Moller-San Pedro M.D., Ph.D. serves as Chief Executive Officer, Director of the Company., is the Chief Executive Officer, Director of the Company. Dr. Møller has served as our Chief Executive Officer and has served as a member of our Board of Directors since June 2015. Dr. Møller was the founder of Azanta A/S, or Azanta, a Danish specialty biopharmaceutical company and its Chief Executive Officer from 2009 to 2015. In addition, Dr. Møller co-founded Genmab A/S ("Genmab"), one of the largest European biopharmaceutical companies in 1999, where he served as Executive Vice President and Chief Operating Officer until 2008. Dr. Møller has also held previous executive management positions at various biopharmaceutical companies, including Executive Vice President, Chief Medical and Chief Operating Officer of OXiGENE, Inc., and Medical Director of Synthélabo Scandinavia. Dr. Møller received his M.D. and Ph.D. degrees from the University of Copenhagen.

What is the salary of Claus Pedro?

As the Chief Executive Officer and Director of Y-Mabs Therapeutics Inc, the total compensation of Claus Pedro at Y-Mabs Therapeutics Inc is $967,497. There are no executives at Y-Mabs Therapeutics Inc getting paid more.

How old is Claus Pedro?

Claus Pedro is 58, he's been the Chief Executive Officer and Director of Y-Mabs Therapeutics Inc since . There are 4 older and 14 younger executives at Y-Mabs Therapeutics Inc. The oldest executive at Y-Mabs Therapeutics Inc is Dr. Torben Lund-Hansen, 70, who is the Sr. VP & Chief Technical Officer.

What's Claus Pedro's mailing address?

Pedro's mailing address filed with the SEC is C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE SUITE 3350, NEW YORK, NY, 10169.

Insiders trading at Y-Mabs Therapeutics Inc

Over the last 6 years, insiders at Y-Mabs Therapeutics Inc have traded over $85,284,951 worth of Y-Mabs Therapeutics Inc stock and bought 1,819,126 units worth $23,554,756 . The most active insiders traders include James Healy, Thomas Gad, and Johan Wedell Wedellsborg. On average, Y-Mabs Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $494,414. The most recent stock trade was executed by Torben Lund Hansen on 28 August 2024, trading 50,000 units of YMAB stock currently worth $219,000.

What does Y-Mabs Therapeutics Inc do?

y-mabs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. the company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express gd2 and b7-h3, respectively. our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. with the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.

Complete history of Claus San stock trades at Y-Mabs Therapeutics Inc

Y-Mabs Therapeutics Inc executives and stock owners

Y-Mabs Therapeutics Inc executives and other stock owners filed with the SEC include:

• Dr. Claus Juan Møller San Pedro M.D., Ph.D.,
  CEO & Director
• Claus Moller-San Pedro,
  Chief Executive Officer, Director
• Thomas Gad,
  Chairman of the Board, President, Founder, Head of Business Development and Strategy
• Thomas Gad,
  Founder, Chairman, Pres and Head of Bus. Devel. & Strategy
• Bo Kruse,
  Chief Financial Officer, Executive Vice President, Treasurer, Secretary, Director
• Bo Kruse,
  Exec. VP, Sec., Treasurer & CFO
• David Gill,
  Independent Director
• James Healy,
  Independent Director
• Ashutosh Tyagi,
  Independent Director
• Gerard Ber,
  Independent Director
• Johan Wedell-Wedellsborg,
  Independent Director
• Torben Lund-Hansen,
  Senior Vice President, Chief Technical Officer
• Steen Lisby,
  Senior Vice President, Chief Medical Officer
• Philip Herman,
  Senior Vice President and Chief Commercial Officer
• Mahiuddin Ahmed,
  Senior Vice President, Chief Scientific Officer
• Joris Wilms,
  Chief Operating Officer, Senior Vice President
• Sue Smith,
  Sr. VP & Chief Commercial Officer
• Dr. Torben Lund-Hansen,
  Sr. VP & Chief Technical Officer
• Joris Wiel Jan Wilms,
  Sr. VP & COO
• Dr. Vignesh Rajah,
  Sr. VP & Chief Medical Officer
• Dr. Steen Lisby M.D., M.Sc.,
  Sr. VP & Chief Scientific Officer
• Peter P. Pfreundschuh,
  CFO and Treasurer
• Gregory S Raskin,
  Director
• Ashu Tyagi,
  Director
• Mary Tagliaferri,
  Director
• Laura Hamill,
  Director
• Vignesh Rajah,
  SVP & CHIEF MEDICAL OFFICER
• Biotech Ap S Wg,
  Director
• Susan Laura Smith,
  SVP & CHIEF COMMERCIAL OFFICER
• Michael J Rossi,
  PRESIDENT & CEO